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566Objectives: Orthotopic heart transplantation is the standard of care for end-stage heart disease. Left ventricular
assist device implantation offers an alternative treatment approach. Left ventricular assist device practice has
changed dramatically since the 2008 Food and Drug Administration approval of the HeartMate II (Thoratec,
Pleasanton, Calif), but at what societal cost? The present study examined the cost and efficacy of both treatments
over time.
Methods: All patients who underwent either orthotopic heart transplantation (n¼ 9369) or placement of an im-
plantable left ventricular assist device (n ¼ 6414) from 2005 to 2009 in the Nationwide Inpatient Sample were
selected. The trends in treatment use, mortality, and cost were analyzed.
Results: The incidence of orthotopic heart transplantation increased marginally within a 5-year period. In con-
trast, the annual left ventricular assist device implantation rates nearly tripled. In-hospital mortality from left
ventricular assist device implantation decreased precipitously, from 42% to 17%. In-hospital mortality for or-
thotopic heart transplantation remained relatively stable (range, 3.8%-6.5%). The mean cost per patient in-
creased for both orthotopic heart transplantation and left ventricular assist device placement (40% and 17%,
respectively). With the observed increase in both device usage and cost per patient, the cumulative Left ventric-
ular assist device cost increased 232% within 5 years (from $143 million to $479 million). By 2009, Medicare
and Medicaid were the primary payers for nearly one half of all patients (orthotopic heart transplantation, 45%;
left ventricular assist device, 51%).
Conclusions: Since Food and Drug Administration approval of the HeartMate II, mortality after left ventricular
assist device implantation has decreased rapidly, yet has remained greater than that after orthotopic heart trans-
plantation. The left ventricular assist device costs have continued to increase and have been significantly greater
than those for orthotopic heart transplantation. Because of the evolving healthcare economics climate, with in-
creasing emphasis on the costs and comparative effectiveness, a concerted effort at LVAD cost containment and
judicious usage is essential to preserve the viability of this invaluable treatment. (J Thorac Cardiovasc Surg
2013;145:566-74)Nearly 6 million Americans have had congestive heart fail-
ure diagnosed.1 Congestive heart failure causes more than
55,000 deaths in the United States each year, is responsible
for 5% of all medical admissions, and accounts for direct
costs of more than 35 billion dollars in the United States
each year.1,2 More federal funds are spent on congestive
heart failure in the United States than any other diagnosis,e Department of Surgery, University of Virginia Health System, Charlottes-
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The Journal of Thoracic and Cardiovascular Surgand a disproportionate amount of these funds is spent on
the treatment of advanced heart failure.3 In patients with ad-
vanced disease, the options are limited, and orthotopic heart
transplantation (OHT) is widely accepted as the therapy of
choice, with 1-year post-transplant survival rates of roughly
85%.4 Western societies have supported heart transplanta-
tion as an acceptable use of healthcare resources; however,
the demand for this life-saving treatment far outstrips the
availability of suitable donor organs. The OHT numbers
in the United States have remained stable during the past de-
cade at approximately 2000 patients treated annually,
a mere fraction of the population who could benefit from
this treatment.4
In 1964, the National Institutes of Health artificial heart
program was created with the stated goal of putting
a man-made heart into a human by the end of the decade.
Despite the large investment of both public and private
funds, little palpable progress was made until 2001 when
the landmark Randomized Evaluation of Mechanical Assis-
tance for the Treatment of Congestive Heart Failure
(REMATCH) trial demonstrated a stark improvement inery c February 2013
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FIGURE 1. Treatment usage over time showing the number of patients
undergoing either orthotopic heart transplantation (OHT) or left ventricular
assist device (LVAD) implantation from 2005 to 2009.
Abbreviations and Acronyms
LVAD ¼ left ventricular assist device
OHT ¼ orthotopic heart transplantation
NIS ¼ Nationwide Inpatient Sample
Mulloy et al Cardiothoracic Transplantationsurvival when patients with advanced heart failure under-
went HeartMate XVE (Thoratec, Pleasanton, Calif) left
ventricular assist device (LVAD) implantation compared
with those supported with conventional medical therapy.5
In response to that trial, the Centers for Medicare and Med-
icaid Services authorized reimbursement for the use of Food
and Drug Administration-approved LVADs as long-term
destination therapy in October 2003.6,7 More recently,
a second leap forward occurred with the replacement of
first-generation pulsatile LVADs with newer continuous-
flow devices such as the HeartMate II LVAD (Thoratec),
which was approved by the Food and Drug Administration
for bridge-to-transplantation in April 2008 and for destina-
tion therapy in January 2010.8,9
Since the April 2008 approval, the HeartMate II has rap-
idly takenovermarket share as themostwidely used implant-
able LVAD in the United States.10 Additionally, patient
outcomes have rapidly improved with this newer device,
with 1-year survival rates now approximately 80%, a per-
centage almost equivalent to the reference standard of heart
transplantation.10 Although it took 4 decades longer than ex-
pected, the fruits of the 1964 investment have now been real-
ized in the form of the HeartMate II, a man-made artificial
blood pump that can be successfully implanted into a human,
with resulting survival rates almost equivalent to transplanta-
tion. Despite this fantastic feat of modern medicine, the cost
of this achievement and feasibility ofwidespread usemust be
carefully weighed. The purpose of the present study was to
examine both OHT and LVAD usage and cost patterns in
the years surrounding the initial HeartMate II bridge-to-
transplant approval in April 2008—to shed light on current
trends and possibly to help guide future use.T
XMETHODS
Data Sources
Data were abstracted from the 2005 through 2009 Nationwide Inpatient
Sample (NIS). The NIS is the largest Healthcare Cost and Utilization Pro-
ject all-payer inpatient database, sponsored by the Agency for Healthcare
Research and Quality. The NIS contains data frommore than 8 million hos-
pital discharges annually from 1050 hospitals located in 44 states, repre-
senting 95% of all US nonfederal hospital discharges.11 The Agency for
Healthcare Research and Quality has developed appropriately scaled dis-
charge weights to generate national estimates of hospitalizations from
the NIS.12 These weights help compare hospitalization rates across years
despite the varying number of states participating each year. The Health-
care Cost and Utilization Project validates the NIS for biases by comparing
it with other population-based data sets.13 In the present analysis, when
more than 2% of the variables for a particular record had data missing at
random, we excluded the record from the computations. No imputationsThe Journal of Thoracic and Cawere performed, and the data sets were reviewed for any systematically
missing values and accordingly excluded from evaluation. Data reporting
met the NIS data use agreement as established by the Healthcare Cost
and Utilization Project. The NIS databases contain de-identified adminis-
trative level data and were not considered human subjects research and,
hence, were exempted from review by the University of Virginia’s human
investigation committee.
Patient Selection
Patients were identified based on whether they had been recipients of an
OHTor an implantable LVAD. The patients were selected using the ‘‘Inter-
national Statistical Classification of Diseases and Related Health Problems,
9th Revision, Clinical Modification’’ codes. All 15 procedure codes (PR1-
PR15) were queried to identify patients having undergone operative proce-
dures using the following ‘‘International Statistical Classification of
Diseases and Related Health Problems, 9th Revision, Clinical Modifica-
tion’’ codes: OHT, 37.5 (heart replacement procedures), 37.51 (heart trans-
plantation), 33.6 (combined heart–lung transplantation); and LVAD, 37.66
(insertion of implantable heart assist system). Only patients older than 18
years of age were selected. Those with multiple procedural codes were
assigned to the groups according to the first procedure code to avoid the
possibility of double counting any patient record. The records were se-
lected only once per any given group (according to the surgical procedure)
and examined with the intent to perform a comprehensive analysis of the
null hypothesis. Patient risk factors were assessed using 30 different
Agency for Healthcare Research and Quality comorbidities.
Total Charges and Cost-to-Charge
The total charges for each analyzed record were obtained from the
Healthcare Cost and Utilization Project. Computations to calculate costs
were completed by multiplying the total charges from the discharge record
by the all-payer inpatient cost-to-charge ratio. These cost-to-charge ratios
were calculated using annual reports by hospitals to the Centers for Medi-
care and Medicaid Services. The hospital-specific cost-to-charge was com-
puted when available, and the weighted group average was used for
calculations when the hospital-specific cost-to-charge was not available
(approximately 11% of the time).
Outcomes of Interest
Treatment usage, in-hospital mortality, cost, and discharge disposition
after OHT and LVAD were our primary outcomes of interest. Complica-
tions were identified and limited to the hospital admission-recorded ‘‘Inter-
national Statistical Classification of Diseases and Related Health Problems,
9th Revision, Clinical Modification’’ codes. Because the NIS containsrdiovascular Surgery c Volume 145, Number 2 567
TABLE 1. Preoperative patient characteristics
Characteristics
2005 2006 2007
OHT LVAD OHT LVAD OHT LVAD
Patients (n) 1744 811 1696 952 1459 909
Age 50.7  13.2 51.6  13.8 50.7  12.2 53.3  12.4 50.5  13.6 52.9  13.6
Men 74.8 73.6 74.4 72.8 75.0 72.7
Race
White 65.9 72.7 71.3 68.6 64.0 69.0
Black 16.2 15.3 14.4 17.7 16.3 18.5
Hispanic 8.6 5.1 6.6 7.5 12.9 10.7
Asian/Pacific Islander 5.8 3.4 4.4 2.4 2.9 0.6
Native American 0.4 1.7 0.8 0.7 1.6 0.7
Other 3.2 1.7 2.6 3.1 2.4 0.6
Primary Payer
Medicare 28.9 28.1 28.3 22.1 28.1 28.8
Medicaid 11.9 12.5 13 11.2 14.9 14.5
Private insurance 54.9 54.5 47.9 55 47.9 47.3
Other 4.3 21 10.8 36.7 9.1 9.4
Income quartile (low to high)
I 17.2 20.1 19.5 25.1 13.0 23.9
II 23.7 24.3 27.7 17.4 21.4 22.0
III 25.6 31.9 26.6 29.0 23.9 21.3
IV 33.5 23.7 26.3 28.4 41.7 32.8
Comorbidities
HTN 39.9 24.9 41.4 30 35 28.4
COPD 12.7 14.3 12.3 9.9 9.0 14.0
Coagulopathy 27.3 30.2 23.1 31.8 26.5 28.8
Depression 10.7 3.7 9.0 5.3 5.5 1.1
Fluid and electrolyte abnormality 36.9 39.0 38.3 39.6 40.1 40.2
Obesity 6.1 5.0 4.8 5.2 2.6 3.2
Peripheral vascular disease 6.1 4.9 2.4 2.6 2.1 3.9
Elective admission 33.1 25.0 25.7 26.7 23.2 22.0
Admission source
Routine 73.8 38.0 79.2 44.9 71.6 40.9
Another hospital 14.7 32.9 13.0 29.7 16.9 43.5
ER 9.5 25.4 7.2 22.9 11.1 14.4
Other health facility 2.0 3.7 0.6 2.5 0.4 1.3
Data presented as mean SEM or percentages.OHT,Open heart transplantation; LVAD, left ventricular assist device;HTN, hypertension;COPD, chronic obstructive pulmonary
disease; ER, emergency room.
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Xinpatient data only, complications occurring after hospital discharge could
not be evaluated.
Statistical Analysis
The strength of the association between variables was examined using
the appropriate hypothesis test. The significance of the differences between
the unadjusted proportions for categorical variables was evaluated using
the Pearson chi-square test. Differences between the mean values of unad-
justed continuous variables were assessed using single-factor analysis of
variance models. Unadjusted in-hospital mortality across the groups was
calculated. All data were analyzed using IBM SPSS Complex Samples,
version 20 (SPSS, IBM, Armonk, NY).RESULTS
Treatment Usage and Patient Characteristics
From January 2005 to December 2009, 15,783 patients
underwent either OHT or implantation of an LVAD. The568 The Journal of Thoracic and Cardiovascular Surgtrends in treatment usage have shown that OHT increased
marginally during the examined period and was consistent
with thewidely reported2000 heart transplants performed
annually in the United States (Figure 1).4 However, the
LVAD implantation rates nearly tripled, surpassing OHT
for the first time in 2009 (P < .001). The increase in
LVAD implantation rates started in 2008, the same year
the Food and Drug Administration approved the
continuous-flow HeartMate II LVAD. Examining the char-
acteristics of these patients over time, several interesting
observations could be made. First, both treatments were
largely performed on men with an average age of about
50 years (Table 1). Most of these patients were white, but
all racial groups were roughly represented in approximate
proportion to their relative contributions to the US popula-
tion. Across the board, black patients were slightlyery c February 2013
2008 2009 Cumulative
OHT LVAD OHT LVAD OHT LVAD
2243 1444 2227 2298 9369 6414
51.1  13.2 55.0  13.8 46.7  19.5 53.4  13.8 49.9  9.7 53.2  9.2
74.4 77.9 77.9 78.0 75.4 75.9
67.0 68.3 62.3 66.0 66.0 68.2
14.1 15.3 16.7 20.4 15.5 17.9
10.8 9.8 13.6 5.8 10.6 7.6
6.4 3.5 4.2 3.2 4.9 2.8
0.6 0.0 0.0 0.3 0.6 0.5
1.1 3.0 3.2 4.2 2.5 2.9
35.1 39.6 29.3 37.1 30.2 33.1
14.5 13.3 15.2 13.5 14.0 13.1
47.3 43.3 48.9 42.9 49.3 46.9
3 2.7 6.5 4.6 6.4 11.7
20.9 19.7 20.5 21.7 18.6 21.9
27.7 28.0 24.4 27.2 25.2 24.8
26.4 27.7 29.7 29.3 26.7 28.1
25.1 24.6 25.4 21.9 29.5 25.2
34.7 30.6 35.5 34.4 37.1 30.0
12.1 13.1 10.2 14.8 11.3 13.5
22.6 27.6 32.4 35.1 26.5 31.4
11.4 6.5 8.6 7.4 9.3 5.5
39.2 47.4 52.0 49.6 41.8 44.9
4.2 5.9 6.5 10.2 5.0 6.8
3.7 6.0 3.7 7.7 3.7 5.7
20.7 25.6 24.3 23.5 25.2 24.4
61.1 30.6 52.6 31.2 66.4 35.3
23.3 47.0 26.0 52.7 19.5 44.2
14.6 19.5 21.5 12.2 13.4 17.4
1.0 2.9 0.0 3.7 0.8 3.0
TABLE 1. Continued
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Xoverrepresented, given that they constituted 13% of the US
population as of the 2010 census (vs 16% of OHTand 18%
of LVAD), and Hispanic patients were slightly underrepre-
sented, because they constitute 16% of the US population
(vs 11% of OHT and 8% of LVAD).14 All 4 income quar-
tiles, as determined by zip code, were well represented for
both LVAD and OHT, suggesting these life-saving proce-
dures are being offered equally to eligible patients, regard-
less of income. As expected, patients had a variety of
comorbidities, with the most common being hypertension,
fluid and electrolyte abnormalities, diabetes, coagulopathy,
and renal failure. Most admissions for heart transplantation
were routine; however, this percentage declined over time.
LVAD recipients were more likely to have been transferred
from another hospital or admitted through the hospital
emergency department.The Journal of Thoracic and CaMortality
All mortality estimates examined mortality before hospi-
tal discharge only. As expected, mortality for OHTwas low,
ranging from 3.8% to 6.5%. Mortality for LVAD implanta-
tion was high but decreased dramatically during the exam-
ined period, from 42.3% in 2005 to 17.0% in 2009
(P< .001; Figure 2). Major improvements in the LVAD
mortality rates started in 2008, the same year Food and
Drug Administration approval of the HeartMate II LVAD
occurred. Therefore, despite any learning curve issues that
often accompany the initial use of a new device, mortality
continued to decline.
Cost
All cost estimates referred to the index procedure hospi-
talization only and did not include the follow-up costs ofrdiovascular Surgery c Volume 145, Number 2 569
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Xoutpatient treatment or subsequent hospitalizations. From
2005 to 2009, the unadjusted mean per-patient cost in-
creased for both OHT and LVAD. The OHT cost increased
by 40% from $120,413 to $168,576, and the LVAD cost in-
creased by 17% from $177,508 to $208,522 (Figure 3, A).
When combining the per-patient cost increases with the dra-
matic increase in treatment usage, the approximated nation-
wide annual expenditures for LVAD procedure admissions
more than tripled, from $143 million in 2005 to $479 mil-
lion in 2009 (Figure 3, B). Similarly, the approximated na-
tional OHTexpenditures increased by more than 50% from
$210 million to $375 million. When combined, the nation-
wide total cost of both OHT and LVAD procedure admis-
sions was $854 million in 2009 alone and $2.5 billion
from 2005 to 2009. The percentage of patients receiving
an OHTor LVAD who were covered by Medicare and Med-
icaid increased over time to roughly one half of all patients.
In 2005, the approximatedMedicare andMedicaid expendi-
tures on OHT hospitalizations totaled about $85 million.
This nearly doubled, reaching roughly $167 million in
2009. Similarly, the approximated Medicare and Medicaid
expenditures on LVAD hospitalizations more than quadru-
pled, from $57 million in 2005 to more than $241 million
in 2009.
Disposition
Those patients discharged alive were classified according
to routine discharge to home, discharge home with home
health services, discharge to a skilled nursing facility or in-
termediate care facility, or discharge to a rehabilitation unit
or short-term hospital. The OHT survivors had routine dis-
charge to home more frequently, and the LVAD recipients
were more likely to be discharged to a skilled nursing facil-
ity or intermediate care facility or to receive home health
services after discharge (Figure 4). This was perhaps not
surprising, because the LVAD recipients might require in-
creased assistance with care of the driveline exit site wound
and need assistance familiarizing themselves and their fam-
ilies with the additional aspects of the device, including
proper care of the power-based unit, control unit, batteries,
and battery pack. The usage of home health services in-
creased for both OHT and LVAD recipients throughout
the study period.
DISCUSSION
The present study has shed light on evolving trends in the
surgical treatment of advanced heart failure on a national
level and provides reason for both great optimism and grave
concern. In the 5 short years from 2005 to 2009, the LVAD
implantation rates nearly tripled and in-hospitalmortality de-
creased by more than one half. This rapid and significant de-
crease in procedure-related mortality on a national level is
likely unprecedented and speaks to themomentous improve-
ments being made in the field of mechanical circulatory570 The Journal of Thoracic and Cardiovascular Surgassistance. Despite this, during the same short period, per pa-
tient, the LVAD hospitalization cost increased by 17% and
the nationwide estimatedLVADhospitalization expenditures
more than tripled. On the one hand, the dramatic improve-
ment witnessed in LVAD mortality during the short study
period suggests the future of LVAD therapy is bright and lim-
itless. On the other hand, the accelerating increase in the
nationwide cost of this treatment cast doubts on the future
financial viability of this invaluable therapy. In presenting
these data, we do not intend to argue either the former or
the latter point of view. That argument rests on the question
of what a life, a year, or a month is worth and was outside
the scope of this project.Wewish solely to point out the facts,
provide information for discussion, andurge consideration of
these questions as our specialty embarks on an era in which
the promises of the 1964 National Institutes of Health artifi-
cial heart program are finally now a reality.
History often has a way of repeating itself, albeit with
slight variations. In 1980, when considering a decision of
whether Medicare would begin reimbursement for heart
transplantation procedures, the Secretary of the Department
of Health and Human Services, Patricia Roberts Harris,
commissioned a major study to examine ‘‘all aspects of
heart transplants, including the scientific, social, economic,
and ethical issues, and, in particular, the impact of a possible
Medicare decision to pay for heart transplants on the Medi-
care program, Medicare beneficiaries, and providers of
health care.’’15,16 The Secretary further argued that
Department of Health and Human Services would require
future new technologies to demonstrate their beneficial
‘‘social consequences’’ before ‘‘financing their wide
distribution.’’17 Fortunately, a decision was made to cover
heart transplantation despite its high cost and, at the time,
variable outcomes. Heart transplantation has since saved
tens of thousands of lives and remains the reference stan-
dard against which all other therapies for advanced heart
failure are judged. The field of mechanical circulatory assist
now finds itself at a similar crossroads. Clearly, LVADs can
no longer be considered merely an experimental therapy;
however, their place in the larger picture of societal care
of the patients with heart failure is still somewhat undefined,
especially when it comes to destination therapy.
To shed insight on these considerations, multiple previous
studies have addressed the issue of LVAD cost, and several
have looked beyond the cost at efforts to define quality. A
cost analysis of a subset of patients in the Randomized Eval-
uation of Mechanical Assistance for the Treatment of
Congestive Heart Failure trial showed that cost of the
implant-related hospitalization averaged $210,187.18 Three
years later, a single-institution analysis demonstrated
a reduction of 40%, with implant hospitalization cost averag-
ing $128,084, suggesting that with experience, care could be
streamlined and the cost reduced.6 A more recent study ana-
lyzed the costs of a subset of patients in the HeartMate IIery c February 2013
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FIGURE 3. Estimated cost of index hospitalization for either orthotopic
heart transplantation (OHT) or left ventricular assist device (LVAD) implan-
tation. A, Mean per-patient cost for OHT and LVAD from 2005 to 2009, in
thousands of US dollars. B, Total nationwide expenditures for OHT and
LVAD index hospitalizations from2005 to 2009, shown in billions ofUSdol-
lars. C, TotalMedicare andMedicaid expenditures for OHTand LVAD index
hospitalizations from 2005 to 2009, shown in billions of US dollars.
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FIGURE 2. Unadjusted in-hospital mortality showing percentage of pa-
tients dying during the index hospitalization for either orthotopic heart
transplantation (OHT) or left ventricular assist device (LVAD) implantation
from 2005 to 2009.
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Xdestination therapy trial19 and found that inflation-adjusted
hospital cost averaged $193,812, very similar to our nation-
wide estimates.20 In an effort to address quality, Rogers and
colleagues21 recently compared the LVAD costs and out-
comeswith those for optimalmedicalmanagement and dem-
onstrated that although theLVADcostsweremuchgreater for
a 5-year period ($360,407 vs $62,856), the quality-adjusted
life years were also greater with LVAD (1.87 vs 0.37). Using
these data, the incremental cost-effectiveness ratio of a con-
tinuous-flow LVAD was calculated to be $198,184 per
quality-adjusted life year. Typically, $50,000 per quality-
adjusted life year is used as the benchmark to determine ad-
equate cost-effectiveness of a given treatment. Therefore,
despite the rapid improvements beingmade inLVADtherapy,
significant progress is still needed to meet accepted cost-
effectiveness benchmarks.
Although the cited studies provide useful information for
a conversation on the relative merits of LVAD therapy, no
previous studies have used a national database to compare
LVAD cost to the standard of OHT. We believe the present
study adds to the discussion by effectively providing
a ‘‘bird’s eye’’ view of the changes occurring in the surgical
treatment of advanced heart failure. To determine the ‘‘so-
cial consequences’’ of LVAD therapy before ‘‘financing
their wide distribution,’’ this larger perspective must be cap-
tured. As healthcare distribution in the United States
changes and evolves, the pressures of cost containment
and comparative effectiveness will inevitably affect the
availability of various treatment approaches and surgical
options for patients with advanced heart failure. To remain
a part of that conversation and to help influence the coming
changes, our field must take a proactive approach, keeping
the best interests of both our patients and our larger commu-
nity in mind. With the field of mechanical circulatory assist
at a crossroads, care must be taken with regard to the dis-
semination of this new technology. Perhaps a concertedThe Journal of Thoracic and Cardiovascular Surgery c Volume 145, Number 2 571
0 
10 
20 
30 
40 
50 
60 
70 
80 
2005 2006 2007 2008 2009 
Routine Home Health SNF/ICF Short-Term Hospital 
0 
10 
20 
30 
40 
50 
60 
70 
80 
2005 2006 2007 2008 2009 
Routine Home Health SNF/ICF Short-Term Hospital 
%
 o
f  
to
ta
l d
isc
ha
rg
es
 
OHT 
LVAD 
Discharge Disposition 
%
 o
f  
to
ta
l d
isc
ha
rg
es
 
FIGURE 4. Discharge disposition of patients discharged alive after under-
going either orthotopic heart transplantation (OHT) or left ventricular assist
device (LVAD) implantation from 2005 to 2009. Data shown as percentages
of total discharges grouped according discharge disposition: routine, home
with home healthcare, skilled nursing facility or intermediate care facility
(SNF/ICF), and short-term hospital.
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Xeffort toward approaching established cost-effectiveness
benchmarks, although improved efficiency and streamlined
care, should precede thewidespread use of LVAD therapy to
nonheart transplant centers around the United States. Prog-
ress does not come easily in any field and especially with the
future envisioned in 1964 finally now in clear view, it would
be difficult to turn back. We intend to pursue the future of
ventricular assist and heart transplantation but always
hope to maintain a realistic awareness of the greater sur-
roundings within which we operate.Study Limitations
A number of potential limitations of the present study are
worth noting. First, the NIS is an administrative discharge
database, and patients cannot be tracked after leaving the
hospital. Therefore, all cost and mortality rates reported
referred to the index admission only, and we were unable
to extrapolate the cost or mortality related to subsequent
admissions during the same year or in succeeding years.
Similarly, we could not determine which or how many
LVAD recipients underwent subsequent heart transplanta-
tion. For these 2 reasons, our cost approximations have
surely underestimated the true per-patient cost of these572 The Journal of Thoracic and Cardiovascular Surgtherapies. Furthermore, the NIS derives data from a 20%
yearly sample of US hospitals with the sample designed
to approximate the national distribution of certain hospital
characteristics, including volume, academic status, loca-
tion, and size. Although the NIS sampling procedure is sta-
tistically sound and has been used extensively to research
national trends in healthcare delivery, elements of our pre-
sented data could reflect year-to-year sampling variations.
Additionally, granularity is limited, and we could not exam-
ine individual patient characteristics. Similarly, no quality
of life data were available, and we had no mechanism to
compare the relative quality of life after LVAD or OHT
nor could we address the quality-adjusted life years or
any similar computations. Despite these potential limita-
tions, the NIS data set allows for analysis of a large sample
size with a wide geographic distribution, providing an ex-
cellent data source for examination of healthcare trends
over time.CONCLUSIONS
LVADs offer a promising alternative to OHT for those pa-
tients with advanced heart failure who are either ineligible
for transplantation or for whom an acceptable donor organ
is not yet available. From 2005 to 2009, the nationwide
LVAD implantation rates nearly tripled, surpassing the heart
transplantation rates for the first time in 2009. During the
same period, mortality during the LVAD implantation hos-
pitalization decreased from 42% to 17%. Most of this
growth in device usage occurred after Food and Drug
Administration approval of the HeartMate II LVAD for
bridge-to-transplantation in April 2008. From 2005 to
2009, the per-patient LVAD cost increased a modest 17%;
however, combined with the increasing usage rates, esti-
mated LVAD implantation expenditures increased by
more than 200% to almost one half a billion dollars in
2009. In January 2010, the HeartMate II LVAD was ap-
proved for destination therapy, and newer continuous-flow
devices still in development will soon follow suit. As the
technology and experience progress, LVAD outcomes will
continue to improve and are rapidly approaching the refer-
ence standard of heart transplantation. In the coming years,
a society that has long footed the bill for heart transplanta-
tion will have to determine when, and whether, additional
progress is worth the price.References
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XDiscussion
Dr Ranjit John (Minneapolis, Minn). Members of the Associ-
ation and guests, I appreciate the opportunity to discuss this timely,
important, and well-presented report by Dr Mulloy and his col-
leagues. My conflict of interests include receiving grant support
from Thoratec and HeartWare.
Although heart transplantation and LVADs represent therapeu-
tic options for the same disease, namely heart failure, the applica-
bility of both these treatments differs vastly in terms of their
availability, timing, and acuity of the patients. Although studies
such as these are useful and provide a good reality check on how
our healthcare dollars are being spent, they sometimes ignoreThe Journal of Thoracic and Cathe fact that the LVAD groups are often a much sicker cohort of
patients, who are often in need of immediate therapy.
Furthermore, I believe studies such as these do not consider the
costs in terms of quality of life years, the functional improvements
of LVADs, and, also, importantly, the dramatic effect that, in par-
ticular, the newer generation of LVADs have had on significantly
reducing wait list mortality, now in the very low single-digit range.
Another comment includes that in the current era, the actual
cost of the LVAD, I mean the pump, represents almost 50% of
the overall cost, nearly $100,000. Thus, it is possible, or perhaps
feasible, that with an increased number of these devices and
a more competitive environment, the costs of these devices could
decrease further. I have 3 questions for you.
My first question is whether the results of your study, and you
briefly mentioned it in your discussion, warrant a closer examina-
tion of the guidelines for approving centers to deliver high and ex-
pensive care such as LVADs, especially in view of a trend toward
the increasing availability of LVADs as a therapeutic option?
Dr Mulloy. Regarding your question about the guidelines for
LVAD availability, obviously both of these treatments are incred-
ibly expensive, and, from our standpoint, LVADs are really not
quite ready for a widespread role out in nontransplant hospitals
all over the United States. Our data, and data from others, suggest
that there is still some room for improvement in outcomes and, es-
pecially, in costs. We do not want to advocate, in any sense, a re-
striction of access but just want to ensure that this is done in
a thoughtful and safe way. We do recognize that for centers to be-
come destination therapy centers, there are a number of regulatory
and quality ‘‘hoops to jump through,’’ and I think these regulations
should be embraced as a positive measure toward ensuring that the
dissemination of this new technology is managed safely.
Our specialty, in general, has done avery good jobofpolicingour-
selves through the Society of Thoracic Surgeons and Interagency
Registry for Mechanically Assisted Circulatory Support (INTER-
MACS) databases and the like. I think it is very important to continue
to examine both quality and costs as LVAD therapy is expanded.
There is tremendous pressure to expand this therapy tomany dif-
ferent centers; however, we just urge caution and focus on improv-
ing outcomes and costs before doing that on a widespread level.
Dr John. My second question relates to a study that was pub-
lished last year in the Annals of Thoracic Surgery. Specifically
after Food and Drug Administration approval in a study of almost
1500 HeartMate II LVADs, a significant trend was seen toward
reducing mortality and improving outcomes. Do you believe we
are on the right track toward improving outcomes and thereby
reducing costs or could you outline points that we should be doing
to further reduce costs?
DrMulloy. I definitely agree that as far as improving outcomes,
the study you mentioned and our results both suggest that we are
on that right track. We saw a decrease from 42% to 17% mortality
within just a 4- or 5-year period and to see that on a national level is
almost unprecedented. The outcomes are obviously rapidly im-
proving with Food and Drug Administration approval of the Heart-
Mate II and then with future LVADs coming down the pipeline.
However, I do not think the evidence is there to say that the costs
are also improving. Theoretically, if you have a decrease in compli-
cations and have a shorter hospital stay, the cost of the procedure-
related hospitalization should definitely decrease. However, asrdiovascular Surgery c Volume 145, Number 2 573
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Xpatients live longer, other unforeseen costs will arise, including in-
creased complications, such as bleeding, arrhythmias, and driveline
infections. Thus, I think to say just by improving outcomes we are
going to decrease costs, the evidence just is not there to say that.
Certainly, as you pointed out earlier, the cost of these devices
occupy a huge portion of the total cost of this therapy. Decreasing
the cost of the device would obviously help. I do not think that is
going to happen without some type of external regulatory pressure.
However, as devices improve, with transcutaneous batteries and
elimination of the driveline and smaller devices, the potential def-
initely exists to decrease all those costs.
In summary, the evidence clearly shows that outcomes are im-
proving but the costs of LVADs are not.
Dr John.My final question relates to heart transplantation. For
a therapy that has not changed significantly in terms of its conduct
in the past 20 years, could you speculatewhy the costs increased by
40% during a 4-year period?
Dr Mulloy. That is an excellent question and thank you for
pointing that out. We were surprised to see that. I do need to com-
ment that all these costs are unadjusted costs; that is, we did not
adjust for inflation, mainly because it was such a short period. In-
flation from 2005 to 2009 on the national level was estimated to be
about 8%. Thus, we can state that 8% of that 40%might have been
inflation related.
Probably more important is that a larger number of patients un-
dergoing transplantation have pre-existing LVADs and we are
probably really starting to see that in 2008 and 2009 and also going
forward. I know at our institution, more than 90% of the patients
currently transplanted have a pre-existing LVAD.
Although these LVAD-supported patients might be healthier on
some levels, given their improved end-organ perfusion, transplan-
tation in the setting of a LVAD definitely add some other issues.
There is increased blood product use, which is extremely expen-
sive and carries risk of additional complications. There is defi-
nitely a learning curve associated with transplantation of patients
with a LVAD in place, and I think that might be where some of
that cost increase occurred.
There is 1 figure that I presented in the report but did not have
time for in the presentation in which we showed whether the pa-
tients were discharged routinely to home, home health, a skilled
nursing facility, and so forth. During the 5 years studied, we ob-
served an increase in both discharge with home health and dis-
charge to skilled nursing facilities for transplant patients. Again,
that trend is likely related to the additional issues associated
with transplantation of patients with a pre-existing LVAD and
could explain some of the observed cost increase.
Dr John. Thanks again. Excellent presentation.
Dr Matthias Loebe (Houston, Tex). Thank you very much for
this very important communication. I wonder if you can comment,574 The Journal of Thoracic and Cardiovascular Surgbased on your study, on the fact that both heart transplants and
LVAD implantations are covered by the same diagnosis-related
group and whether it would not make more sense to separate the
2 to have a better idea of the expenses for both heart transplanta-
tions and LVAD implantations, in particular, because, today,
more patients receive LVADs than heart transplants?
DrMulloy. I have to admit, I am a research fellow, and I am not
very familiar with the diagnosis-related group or billing from the
clinical standpoint. Certainly, going forward, we do need to differ-
entiate the costs of these separate therapies and also consider the
sum costs of both, which is something we were unable to do in
the present study. Taking our former Vice-President as an example,
obviously our estimate of $209,000 would incredibly underesti-
mate the total cost directed at a single patient who has received
both an LVAD and a heart transplant. But, sorry, I am unable to ad-
dress your specific diagnosis-related group question.
Dr Kenneth Liao (Minneapolis, Minn). My question is did you
notice any difference between the INTERMACS different levels
and then related with the cost? For example, INTERMACS level
I would cost much more than INTERMACS level III or IV. Can
you comment on that?
Dr Mulloy. That is, unfortunately, something the database pre-
vents us from being able to study. It is definitely a limitation of
a database study, in which we are relying completely on the ‘‘In-
ternational Statistical Classification of Diseases and Related
Health Problems, 9th Revision, Clinical Modification’’ codes to
determine these numbers. That is a very interesting question, but
it is just not something that we were able to study.
Dr Friedhelm Beyersdorf (Freiberg, Germany). I just want to
make a short remark. Terminal heart failure is a huge problem,
concerns the number of patients and the costs for the insurance
companies to treat these patients, and these are costs go into bil-
lions per year. Of the entire sum that has to be spent for terminal
heart failure treatment, less than 5% is in the direction of the sur-
gical treatment. Thus, I just would like to encourage you to de-
velop the surgical treatment still further. The medical treatments
cost so much with rehospitalization and all the other treatments
that, definitely, we can provide good service to our patients,
although for the individual patients, the costs are there, and you
have shown this very clearly. However, it should be seen in com-
parison to the overall costs.
Dr Mulloy. Thank you for making that point. We do not intend
to argue that we should not push forward with LVAD or additional
surgical therapy for heart failure by any means. We just want to
make the point that this should be done thoughtfully, while keep-
ing these costs in mind. We all know that the cost environment in
the United States is changing, with an increased focus on compar-
ative effectiveness, and we just want to bring these concerns to
everyone’s attention as something to think about as we go forward.ery c February 2013
